Navigation Links
Top-line Data Show AcelRx Pharmaceuticals' ARX-04 Achieves Primary Endpoint in Dose-Finding Phase 2 Clinical Trial
Date:4/24/2013

d the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to: the ability of AcelRx Pharmaceuticals to successfully complete the clinical trials for the sufentanil NanoTab System; that subsequent analyses of data by regulatory agencies may be subject to differing interpretations;  the success, cost and timing of all product development; the uncertain clinical development process, including the risk that clinical trials have an effective design or deliver data on schedule; AcelRx Pharmaceutical's ability to attract funding partners or collaborators with development, regulatory and commercialization expertise; its ability to obtain sufficient financing to complete registration of its product candidates in the United States and Europe; its ability to obtain and maintain regulatory approvals of its product candidates in the United States and Europe; the market potential for its product candidates; the accuracy of AcelRx Pharmaceuticals' estimates regarding expenses, capital requirements and needs for financing; and other risks detailed in the "Risk Factors" and elsewhere in AcelRx Pharmaceuticals' U.S. Securities and Exchange Commission filings and reports, including its Annual Report on Form 10-K filed with the SEC on March 12, 2013.  AcelRx Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

(Logo: http://photos.prnewswire.com/prnh/20130226/MM67303LOGO)


'/>"/>
SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sinovac EV71 Vaccine Phase III Top-Line Results Presented at 13th Annual World Vaccine Congress & Expo
2. AstraZeneca Announces Top-Line Results From OSKIRA-1 Phase 3 Study of Fostamatinib in Rheumatoid Arthritis
3. Merrimack Pharmaceuticals Announces Top-Line Results From A Single Arm Phase 2 Advanced Lung Cancer Study In Patients With Resistance To An Anti-EGFR Tyrosine Kinase Inhibitor
4. AcelRx Top-line Data Show Primary Endpoint Achieved in Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Post-Operative Pain in Major Open Abdominal Surgery Patients
5. Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings
6. AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis
7. AcelRx Announces Achievement of the Primary End-Point in Phase 3 Comparative Study Involving the Sufentanil NanoTab PCA System and Plans to Hold a Conference Call and Webcast Tomorrow to Discuss Top-Line Results
8. Vermillion Announces Positive Top-Line Results from the OVA500 Multi-Center Study Led by UC Irvine
9. Top-line Data From Phase 3 Trial of Ataluren in Patients with Nonsense Mutation Cystic Fibrosis Show Promising Results
10. Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial
11. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014  For over a decade ... no link between vaccines and autism. But at least for ... In a statement , William Thompson , ... information" linking the MMR vaccine to an increased risk of ... of the same data suggests that African American males have ...
(Date:9/2/2014)... Calif. , Sept. 2, 2014 /PRNewswire-iReach/ -- ... just recognized as one of the fastest growing ... past few years, the company has undergone significant ... research, late phase global clinical development, anti-viral and ... 2 years, WCCT Global has successfully participated in ...
(Date:9/1/2014)... Sept. 1, 2014 Reportlinker.com announces that ... its catalogue:  Drug Discovery Technologies - A ... http://www.reportlinker.com/p02349116/Drug-Discovery-Technologies---A-Global-Market-Overview.html The development of new ... requires extensive expenditure, in addition to consuming a ... a new drug involves the utilizing high-throughput screening ...
Breaking Medicine Technology:CDC vaccine scientist admits wrongdoing. 2CDC vaccine scientist admits wrongdoing. 3Contract Research Organization WCCT Global Celebrates Being Named as One of the Fastest Growing Companies in America 2Drug Discovery Technologies - A Global Market Overview 2Drug Discovery Technologies - A Global Market Overview 3Drug Discovery Technologies - A Global Market Overview 4Drug Discovery Technologies - A Global Market Overview 5Drug Discovery Technologies - A Global Market Overview 6Drug Discovery Technologies - A Global Market Overview 7Drug Discovery Technologies - A Global Market Overview 8Drug Discovery Technologies - A Global Market Overview 9Drug Discovery Technologies - A Global Market Overview 10Drug Discovery Technologies - A Global Market Overview 11Drug Discovery Technologies - A Global Market Overview 12Drug Discovery Technologies - A Global Market Overview 13Drug Discovery Technologies - A Global Market Overview 14
... Dec. 21, 2011  Shareholders of Medco Health Solutions, Inc. (NYSE: ... Express Scripts. (Logo: http://photos.prnewswire.com/prnh/20100609/MEDCOLOGO ) ... vote present in person or by proxy at a special ... Merger dated July 20, 2011 by a margin of 99 ...
... 2011 Actavis Group, the international generic pharmaceuticals company, today ... a binding letter of intent (LOI) with QRxPharma Limited (ASX: ... United States.  Under the terms of the ... IR, a patented 3:2 ratio fixed dose combination of morphine ...
Cached Medicine Technology:Medco Shareholders Approve Merger With Express Scripts 2Actavis to Launch Novel Pain Medication in the US 2Actavis to Launch Novel Pain Medication in the US 3
(Date:9/2/2014)... N.J. (PRWEB) September 02, 2014 ... technologies and development solutions for drugs, biologics and ... of its strategic partner, Eli Lilly’s growth, it ... packaging lines at its Philadelphia Clinical Supply Center ... syringe packaging capabilities in its clinical supply facility ...
(Date:9/2/2014)... The performance of the Lotteries ... years. Industry revenue is estimated to grow at a ... through 2014-15, following stabilised growth over the past three ... alternate forms of gambling. Horse and sports betting, poker ... all become increasingly popular over the past five years, ...
(Date:9/2/2014)... Based on new studies, concerns ... kidney and spleen surgeries, have continued to mount. ... patients. , An article in the "Public ... Titilope Oduyebo and Bradley J. Quade called, "Peritoneal ... on Nov 26, 2012 defines a morcellator ...
(Date:9/2/2014)... 2, 2014 (HealthDay News) -- When it comes to excess ... equal, a new study finds. The research found that ... person,s odds for high blood pressure more than overall body ... of high blood pressure. But it wasn,t clear how the ... to researchers at University of Texas Southwestern Medical Center in ...
(Date:9/2/2014)... York (PRWEB) September 02, 2014 ... announces that Class Counsel has filed an application ... awards in the class action litigation brought over ... LLP, the Court-Appointed Class Counsel in this litigation ... Bernstein, LLP; Audet & Partners, LLP; Levin Fishbein, ...
Breaking Medicine News(10 mins):Health News:Catalent Supports Eli Lilly's Growing Global Clinical Trials Needs with New Investment in Automated Packaging Solutions 2Health News:Lotteries in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Lotteries in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:New York Law Firm Discusses Allegedly Dangerous Surgical Morcellator Devices And Cancer Risk 2Health News:New York Law Firm Discusses Allegedly Dangerous Surgical Morcellator Devices And Cancer Risk 3Health News:'Spare Tire' May Be Especially Bad for Your Blood Pressure 2Health News:A Proposed Order Has Been Submitted in A Class Action Law Suit Brought Over Flushmate Toilets, Parker Waichman Announces 2Health News:A Proposed Order Has Been Submitted in A Class Action Law Suit Brought Over Flushmate Toilets, Parker Waichman Announces 3
... a brain cancer death sentence. It is the most lethal ... are diagnosed with GBM annually in the U.S., half ... within 3 years. The treatments include highly invasive surgeries to ... dose, both leading to a very low quality of life. ...
... conducted by the University of Michigan’s researchers has revealed that those ... unsafe are likely to put on weight. As many as 16% ... in the US are reported to be overweight, while in the ... tripled since the early 1990s. ,The researchers, led ...
... one more reason to raise a toast- a formula for ... // can pep-up your spirits and relish the ... University, and author of the formula for Marks & Spencer, ... open a champagne bottle. According to smith, P = T/4.5 ...
... difficult acrobatic stunts and are paying the price with a ... ,Cheerleaders catapult in the air, climb human ... the ground. They also make it to the emergency room. ... Pediatrics estimates that 208,800 young people aged 5 to 18 ...
... that is mainly present in pain relievers. Recently there is ... // clinicians complaining about over dosage of Acetaminophen. ... 50% of these cases are unintentional. Drugs like Tylenol, Benadryl, ... as one of the main composition in them. ...
... smokers or those who have been smoking in the past have ... tomography (CT scan) to detect // lung cancer if any, ... effective treatment and thereby improve the prognosis. ,The ... family history of the dreadful disease. For those of you ...
Cached Medicine News:Health News:Radiology advance points way to non-invasive brain cancer treatment 2Health News:Surroundings Have An Effect On Weight 2Health News:Cheerleaders run high risk of injury-US study 2Health News:Painkillers Lead To Liver Failure 2Health News:CT Scan A Must For Smokers With Family History Of Lung Cancer 2
... navigation for Spine is ... integrate C-arm fluoroscopy with ... 3500 - spine Multi-application ... for ENT, cranial and ...
The ZEPHIR Anterior Cervical Plate System is the lowest profile plate clinically available....
... Mx8000 is a family of multislice CT ... version, Mx8000 also is available in an ... the same friendly user interface, advanced applications ... Both Dual and Quad systems can be ...
... 16 is Philips premium 16-slice CT scanner. ... to automatically delivering high quality, advanced results, the ... a platform that has been the most popular ... comprehensive organ assessment literally within seconds, and with ...
Medicine Products: